CollaGenex Completes Agreement for Periostat

CollaGenex Pharmaceuticals Inc. has finalized an agreement with Applied Analytical Industries Inc. to manufacture Periostat, the company's lead drug for the treatment of periodontal disease.

Under the terms of the agreement, AAI will manufacture Periostat for future sale in the United States. Product manufacturing will begin immediately to ensure that an adequate inventory is available for sale upon regulatory approval.

CollaGenex Pharmaceuticals is an emerging pharmaceutical company that is developing and commercializing medical therapies for the treatment of periodontal disease and other pathologies. The company's core technology involves inhibiting the activity of certain enzymes that destroy the connective tissues of the body.

AAI is a contract research and development organization providing pharmaceutical product development and support services to the pharmaceutical and biotechnology industries. AAI offers seamless outsourcing as well as an integrated broad spectrum of pharmaceutical services, both clinical and non-clinical.

For more information: Nancy Broadbent, CollaGenex Pharmaceuticals. Tel: 215-579-7388